ClinicalTrials.gg
CompletedNCT02954848Updated Aug 2, 2019Results posted

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

A Phase 3 interventional study of Placebo and TAK-438 10 mg in Non-erosive Gastroesophageal Reflux Disease, sponsored by Takeda. Completed at 30 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Enrollment
4th of 16
484 · median 118
Started
2016
the only one that year
Phase 3
3 of 16
1 open now
Registered
3rd of 16
by date
Lead sponsor
3 of 16
Takeda

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 3rd registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).

Read the detailed description

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multi-center study will be conducted to verify the superiority of TAK-438 (TAK-438 10 mg, once daily, 4 weeks) to placebo (placebo, once daily, 4 weeks) in participants with non-erosive gastroesophageal reflux disease (NERD).

The study consists of a 1-week, single-blind run-in period and a 4-week, double-blind treatment period. The participants will receive the study drug (TAK-438 placebo tablet) for the 1-week single-blind run-in period. After the run-in period, eligible participants will be randomized into TAK-438 10 mg or placebo treatment groups in a 1:1 ratio. The randomized participants will receive the assigned study drug (TAK-438 10 mg tablet or placebo tablet) for the 4-week double-blind treatment period.

03

Conditions studied

  • Non-erosive Gastroesophageal Reflux Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written form prior to the initiation of any study procedures.
  3. The participant with NERD.
  4. The participant is endoscopically confirmed to have the modified Los Angeles (LA) Classification Grade N or M at the start of the run-in period (Visit 1).

    To allow efficacy evaluation in the participants with Grade N as well as in those with Grade M, the target number of participants in each grade is at least 30% of the total number of participants. Enrollment of patients with either Grade N or M will end when the number of enrolled participants with each grade exceeds 332, or 70% of the total planned number of participants.

  5. The participant experiences recurrent heartburn, on at least 2 days a week over the last 3 weeks prior to the start of the run-in period (Visit 1).
  6. The participant is either a male or female outpatient with a minimum age of 20 years at the time of informed consent signing. However, participants who are hospitalized only for examination purposes are also allowed to participate.
  7. A female participant of agrees to use routinely adequate from signing of informed consent throughout the duration of the study, and for 4 weeks after the last dose of study drug.
  8. The participant's compliance to the study drug has been good (75% or better) in the run-in period.
  9. The participant has experienced heartburn on at least 2 days in the last 1 week prior to randomization.
  10. The participant has appropriately provided in the patient's diary all the required information during the run-in period.

Exclusion criteria

Exclusion Criteria:

  1. The participant has received any compound within 84 days prior to the first dose of study drug.
  2. The participant has received TAK-438 in a previous clinical study or as a therapeutic agent, except one with experience of receiving TAK-438 as an adjunct therapy for H. pylori eradication, who can be enrolled in this study.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. The participant has donated at least 400 mL of blood within the 90 days prior to the start of the run-in period (Visit 1).
  5. Endoscopic examination for entering this study fails to diagnose NERD within 84 days before the start of the run-in period (Visit 1).
  6. The participant has any complications affecting the esophagus, including Barrett's esophagus (3 cm or more, long segment Barrett's esophagus [LSBE]), eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, and esophageal stenosis; a history of radiation therapy or cryotherapy for the esophagus; or caustic or physiochemical trauma (eg, esophageal sclerotherapy). However, participants with Barrett's mucosa (less than 3 cm, short segment Barrett's esophagus [SSBE]) or Schatzki's ring (a mucosal tissue ring lining the inferior esophageal sphincter) are permitted to participate.
  7. The participant has a history of surgery or treatment affecting gastroesophageal reflux, including fundoplication and mechanical dilatation for esophageal stenosis (except Schatzki's ring), or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps).
  8. The participant has acute upper gastrointestinal bleeding or gastric or duodenal ulcer, characterized by a defective mucosa with white coating, within 30 days prior to the start of the run-in period (Visit 1). However, participants with gastric or duodenal erosion are permitted to participate.
  9. The participant has acute gastritis or acute exacerbation of chronic gastritis.
  10. The participant has, or has a history of, Zollinger-Ellison syndrome or gastric acid hypersecretion disorders.
  11. The participant has, or has a history of chest pain due to cardiac disease, or has chest pain suspectedly caused by cardiac disease within 1 year prior to the start of the run-in period (Visit 1).
  12. The participant has any other concurrent upper gastrointestinal symptoms more severe than heartburn.
  13. The participant has depression.
  14. The participant has, has a history of, or is suspected of functional upper gastrointestinal disorders, such as functional dyspepsia and functional heartburn diagnosed by the Rome IV criteria.
  15. The participant has a history of or allergies to TAK-438 (including the formulation ).
  16. The participant has a history or complication of drug abuse (defined as any illicit drug use) or of alcohol abuse within 1 years prior to the start of the run-in period (Visit 1).
  17. The participant requires any excluded medications or treatments.
  18. The female participant who is pregnant, is lactating, or is intending to become pregnant or to donate ova any time between the signing and 4 weeks after the last dose of study drug.
  19. The participant has any serious neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, endocrinological, or hematologic diseases.
  20. The participant needs surgery requiring hospitalization during the course of the study, or surgery requiring hospitalization is scheduled for the participant during the course of the study.
  21. The participant has a history of or is treated for malignancy within 5 years prior to the start of the run-in period (Visit 1). However, participants who have recovered completely from cutaneous basal cell carcinoma or from cervical carcinoma in situ are permitted to participate.
  22. The participant has acquired immunodeficiency syndrome (AIDS) or hepatitis, is a (HIV) carrier, or tested positive for the virus surface antigen (HBsAg) or the virus (HCV) antibody. However, participants who tested negative for HCV antigen or HCV-RNA are permitted to participate.
  23. The participant has any of the following abnormal clinical laboratory test values at the start of the run-in period (Visit 1):

    • Creatinine > 2 mg/dL.
    • (ALT) or aspartate aminotransferase (AST) > (ULN).
    • (Total bilirubin) > ULN.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
484 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.

    Drug: Placebo

  • Experimental
    TAK-438 10 mg

    TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.

    Drug: Placebo · Drug: TAK-438 10 mg

Interventions

  • DrugPlacebo

    TAK-438 placebo-matching tablets

  • TAK-438 tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Days Without Symptoms of Heartburn

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Reported data was the percentage of days for each group, calculated by the number of days without heartburn divided by the number of days of treatment period.

    Time frame: Up to Week 4

  2. Cumulative Rate of Improvement in Symptoms of Heartburn

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Symptom improvement was defined as symptoms experienced on less than 2 days of the last 7 days. The cumulative data was collected between Day 0 and Day 24 and is reported for the following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA = Not Applicable.

    Time frame: Day 0 to Day 24

  3. Severity of Symptoms of Heartburn

    Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated by the number of severity score in daily diaries.

    Time frame: Up to Week 4

Secondary outcomes

  1. Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2

    Participants recorded the presence and severity of heartburn in a daily participant diary. Percentage of days without heartburn was calculated in each subgroup of the response (improved or not improved) according to Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.

    Time frame: Up to Week 4

  2. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 1) at Week 2

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected were shown as NA = Not Applicable.

    Time frame: Day 0 to Day 22

  3. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 1) at Week 2

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement is calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected were shown as NA = Not Applicable.

    Time frame: Day 0 to Day 24

  4. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 2) at Week 2

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  5. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 2) at Week 2

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. The response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  6. Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2

    Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, the higher scores indicates greater severity. The severity was calculated in each subgroup of response (improved or not improved) according to Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.

    Time frame: Up to Week 4

  7. Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

    Time frame: Up to Week 4

  8. Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N) at Baseline

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. The score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade N per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  9. Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade M) at Baseline

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade M per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  10. Severity of Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

    Time frame: Up to Week 4

  11. Percentage of Days Without Symptoms of Heartburn Stratified by Subgroup of Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to Criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.

    Time frame: Up to Week 4

  12. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

    Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to the mucosa. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 19, 20, and 22. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 22

  13. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  14. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 22

  15. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on \< 2 days of the 7 days prior to Week 2 \[Day 8 to 14\]; Not improved: participants experienced heartburn on \>= 2 days of 7 days prior to Week 2 \[Day 8 to 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  16. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data collected between Day 0 and 22 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 22

  17. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  18. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 24

  19. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe: 4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. Data not collected shown as NA=Not Applicable.

    Time frame: Day 0 to Day 23

  20. Severity of Symptoms of Heartburn in Subgroup Stratified by Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.

    Time frame: Up to Week 4

  21. Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher score indicates greater severity. The percentage was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].

    Time frame: Up to Week 4

  22. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved) to Acid Suppressants in Participants Who Had a Medication History

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23. Data not collected were shown as NA=Not Applicable.

    Time frame: Up to Week 4

  23. Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved) to Acid Suppressants in Participants Who Had a Medication History

    Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 5, 9, 16, 19, and 20. Data not collected were shown as NA=Not Applicable.

    Time frame: Up to Week 4

  24. Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History

    Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].

    Time frame: Up to Week 4

07

Results

Posted Aug 2, 2019

Participant flow

Participants took part in the study at 44 investigative sites in Japan from 15 November 2016 to 26 February 2018.

Participant flow — Overall Study
MilestonePlaceboTAK-438 10 mg
Started245239
Treated245238
Completed243234
Not completed25
Withdrew: Randomized but not treated01
Withdrew: Adverse event23
Withdrew: Withdrawal by participant01

Outcome measures

PrimaryPercentage of Days Without Symptoms of Heartburn

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Reported data was the percentage of days for each group, calculated by the number of days without heartburn divided by the number of days of treatment period.

Time frame:
Up to Week 4
Reported as:
Median · percentage of days
Percentage of Days Without Symptoms of Heartburn
percentage of daysPlaceboTAK-438 10 mg
Percentage of Days Without Symptoms of Heartburn61.50 (0.0 to 100.0)72.55 (0.0 to 100.0)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0643 · Median difference (final values): 3.800 · 95% CI 0.000 to 10.600The point estimate of the median difference between the treatment groups was calculated using the Hodges-Lehmann estimation.
PrimaryCumulative Rate of Improvement in Symptoms of Heartburn

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Symptom improvement was defined as symptoms experienced on less than 2 days of the last 7 days. The cumulative data was collected between Day 0 and Day 24 and is reported for the following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA = Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 114.723.1
Day 215.924.4
Day 316.325.2
Day 417.626.1
Day 518.828.2
Day 619.230.4
Day 720.032.5
Day 821.232.9
Day 923.734.2
Day 10NA35.5
Day 1125.738.5
Day 1227.341.1
Day 1329.044.6
Day 1430.646.7
Day 1531.448.9
Day 1634.349.7
Day 1736.351.0
Day 1838.454.4
Day 1940.055.7
Day 2042.759.0
Day 2144.759.5
Day 2248.662.7
Day 2351.366.1
Day 24NA71.3
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0003
PrimarySeverity of Symptoms of Heartburn

Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated by the number of severity score in daily diaries.

Time frame:
Up to Week 4
Reported as:
Median · score on a scale
Severity of Symptoms of Heartburn
score on a scalePlaceboTAK-438 10 mg
Severity of Symptoms of Heartburn1.140 (0.00 to 2.82)1.070 (0.00 to 3.67)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0826 · Median difference (final values): -0.1100 · 95% CI -0.2400 to 0.0100
SecondaryPercentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2

Participants recorded the presence and severity of heartburn in a daily participant diary. Percentage of days without heartburn was calculated in each subgroup of the response (improved or not improved) according to Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.

Time frame:
Up to Week 4
Reported as:
Median · percentage of days
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2
percentage of daysPlaceboTAK-438 10 mg
Criteria 1, Improved92.00 (41.4 to 100.0)96.00 (46.4 to 100.0)
Criteria 1, Not Improved50.95 (0.0 to 92.9)48.05 (0.0 to 92.9)
Criteria 2, Improved71.40 (3.3 to 100.0)81.15 (14.3 to 100.0)
Criteria 2, Not Improved39.30 (0.0 to 83.3)24.15 (0.0 to 84.0)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0478 · Median difference (final values): 3.300 · 95% CI 0.000 to 5.300
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.8963 · Median difference (final values): 0.000 · 95% CI -6.100 to 6.000
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0120 · Median difference (final values): 5.200 · 95% CI 0.000 to 10.700
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0871 · Median difference (final values): -4.700 · 95% CI -17.400 to 0.000
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 1) at Week 2

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected were shown as NA = Not Applicable.

Time frame:
Day 0 to Day 22
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 1) at Week 2
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 143.455.6
Day 247.058.6
Day 348.260.6
Day 451.862.6
Day 555.467.7
Day 656.672.7
Day 759.077.8
Day 862.778.8
Day 11NA80.8
Day 15NA81.8
Day 1663.9NA
Day 1765.1NA
Day 18NA83.8
Day 1966.3NA
Day 2069.287.6
Day 2170.6NA
Day 2275.593.8
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0025
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 1) at Week 2

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement is calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected were shown as NA = Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 1) at Week 2
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 93.72.2
Day 10NA4.4
Day 116.88.1
Day 129.312.6
Day 1311.718.5
Day 1414.222.2
Day 1515.425.2
Day 1619.126.7
Day 1721.628.9
Day 1824.733.3
Day 1926.635.6
Day 2029.238.7
Day 2131.539.5
Day 2234.941.7
Day 2339.247.0
Day 24NA55.1
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.1059
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 2) at Week 2

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 2) at Week 2
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 121.431.6
Day 223.233.3
Day 323.834.5
Day 425.635.6
Day 526.238.5
Day 626.841.4
Day 728.044.3
Day 829.844.9
Day 932.146.0
Day 10NA47.8
Day 1134.551.8
Day 1236.954.1
Day 1338.757.6
Day 14NA58.2
Day 1539.360.0
Day 1642.361.1
Day 1745.362.3
Day 1847.165.2
Day 1948.366.3
Day 2050.969.5
Day 2152.470.1
Day 2256.771.9
Day 23NA74.5
Day 24NA78.7
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0004
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 2) at Week 2

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. The response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 2) at Week 2
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 52.6NA
Day 95.21.6
Day 116.5NA
Day 12NA4.9
Day 137.88.2
Day 1413.014.8
Day 1514.318.0
Day 1616.9NA
Day 17NA19.7
Day 1819.524.6
Day 1922.126.2
Day 2024.929.7
Day 2127.9NA
Day 2231.337.0
Day 2341.142.7
Day 24NA50.9
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.5393
SecondarySeverity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2

Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, the higher scores indicates greater severity. The severity was calculated in each subgroup of response (improved or not improved) according to Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.

Time frame:
Up to Week 4
Reported as:
Median · score on a scale
Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2
score on a scalePlaceboTAK-438 10 mg
Criteria 1, Improved0.420 (0.00 to 1.44)0.310 (0.00 to 1.56)
Criteria 1, Not Improved1.430 (0.25 to 2.82)1.420 (0.14 to 2.64)
Criteria 2, Improved0.960 (0.00 to 2.14)0.675 (0.00 to 2.04)
Criteria 2, Not Improved1.610 (0.44 to 2.82)1.740 (0.43 to 3.67)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0505 · Median difference (final values): -0.1000 · 95% CI -0.2100 to 0.0000
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.8138 · Median difference (final values): 0.0200 · 95% CI -0.1200 to 0.1500
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0129 · Median difference (final values): -0.1500 · 95% CI -0.2800 to -0.0300
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0765 · Median difference (final values): 0.1700 · 95% CI -0.0100 to 0.3600
SecondaryPercentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

Time frame:
Up to Week 4
Reported as:
Median · percentage of days
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline
percentage of daysPlaceboTAK-438 10 mg
Grade N64.15 (0.0 to 100.0)76.70 (0.0 to 100.0)
Grade M60.70 (0.0 to 100.0)67.90 (0.0 to 100.0)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1490 · Median difference (final values): 6.500 · 95% CI -1.900 to 15.300
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.2146 · Median difference (final values): 3.600 · 95% CI -1.400 to 10.700
SecondaryCumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N) at Baseline

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. The score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade N per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N) at Baseline
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 118.322.2
Day 2NA23.5
Day 319.524.7
Day 4NA27.2
Day 523.229.7
Day 624.432.3
Day 726.836.0
Day 828.037.3
Day 929.341.0
Day 1134.143.5
Day 1236.647.3
Day 13NA51.1
Day 14NA54.8
Day 15NA57.3
Day 1639.0NA
Day 1740.258.6
Day 1843.961.1
Day 1946.363.6
Day 2047.766.3
Day 2149.167.7
Day 2252.173.4
Day 23NA78.7
Day 24NA89.4
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0059
SecondaryCumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade M) at Baseline

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade M per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade M) at Baseline
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 112.923.6
Day 214.724.9
Day 3NA25.5
Day 416.6NA
Day 5NA27.5
Day 6NA29.4
Day 7NA30.7
Day 817.8NA
Day 920.9NA
Day 10NA32.7
Day 1121.535.9
Day 1222.737.9
Day 1325.241.2
Day 1427.642.5
Day 1528.844.4
Day 1631.945.7
Day 1734.447.0
Day 1835.651.0
Day 1936.951.6
Day 2040.355.1
Day 2142.6NA
Day 2247.057.1
Day 2350.859.6
Day 24NA63.3
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0153
SecondarySeverity of Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

Time frame:
Up to Week 4
Reported as:
Median · score on a scale
Severity of Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline
score on a scalePlaceboTAK-438 10 mg
Grade N1.070 (0.00 to 2.82)0.850 (0.00 to 3.67)
Grade M1.180 (0.00 to 2.54)1.110 (0.00 to 2.64)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0757 · Median difference (final values): -0.1800 · 95% CI -0.4300 to 0.0200
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.3837 · Median difference (final values): -0.0700 · 95% CI -0.2200 to 0.0900
SecondaryPercentage of Days Without Symptoms of Heartburn Stratified by Subgroup of Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to Criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.

Time frame:
Up to Week 4
Reported as:
Median · percentage of days
Percentage of Days Without Symptoms of Heartburn Stratified by Subgroup of Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)
percentage of daysPlaceboTAK-438 10 mg
Criteria 1, Grade N and Improved93.00 (41.4 to 100.0)92.90 (46.4 to 100.0)
Criteria 1, Grade N and Not Improved53.60 (0.0 to 92.6)53.60 (0.0 to 92.9)
Criteria 1, Grade M and Improved89.30 (56.0 to 100.0)96.40 (59.3 to 100.0)
Criteria 1, Grade M and Not Improved49.05 (0.0 to 92.9)44.40 (0.0 to 92.9)
Criteria 2, Grade N and Improved69.00 (3.6 to 100.0)79.30 (39.3 to 100.0)
Criteria 2, Grade N and Not Improved50.00 (0.0 to 83.3)22.95 (0.0 to 84.0)
Criteria 2, Grade M and Improved73.30 (3.3 to 100.0)82.10 (14.3 to 100.0)
Criteria 2, Grade M and Not Improved33.90 (0.0 to 78.6)25.00 (0.0 to 78.6)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.6631 · Median difference (final values): 0.000 · 95% CI -5.000 to 3.500
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.5627 · Median difference (final values): 3.200 · 95% CI -7.100 to 13.900
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0042 · Median difference (final values): 3.700 · 95% CI 0.000 to 8.000
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.6452 · Median difference (final values): -0.700 · 95% CI -9.400 to 6.400
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0376 · Median difference (final values): 7.400 · 95% CI 0.000 to 17.800
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1600 · Median difference (final values): -13.000 · 95% CI -35.700 to 3.600
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1032 · Median difference (final values): 3.600 · 95% CI 0.000 to 10.700
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.2613 · Median difference (final values): -3.300 · 95% CI -14.300 to 0.200
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to the mucosa. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 19, 20, and 22. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 22
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 153.646.2
Day 2NA48.7
Day 357.151.3
Day 4NA56.4
Day 567.961.5
Day 671.466.7
Day 778.674.4
Day 882.176.9
Day 11NA79.5
Day 1985.7NA
Day 20NA82.9
Day 2289.3100.0
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.9970
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 91.97.3
Day 119.39.8
Day 1213.017.1
Day 13NA24.4
Day 14NA31.7
Day 15NA36.6
Day 1616.7NA
Day 1718.539.0
Day 1824.143.9
Day 1925.948.8
Day 2027.951.2
Day 2130.153.8
Day 2232.4NA
Day 23NA63.0
Day 24NA81.5
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0125
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 22
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 138.261.7
Day 243.665.0
Day 3NA66.7
Day 449.1NA
Day 5NA71.7
Day 6NA76.7
Day 7NA80.0
Day 852.7NA
Day 11NA81.7
Day 15NA83.3
Day 1654.5NA
Day 1756.4NA
Day 18NA86.7
Day 2060.890.5
Day 2163.0NA
Day 2268.3NA
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0004
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on \< 2 days of the 7 days prior to Week 2 \[Day 8 to 14\]; Not improved: participants experienced heartburn on \>= 2 days of 7 days prior to Week 2 \[Day 8 to 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 94.6NA
Day 10NA3.2
Day 115.67.4
Day 127.410.6
Day 1311.116.0
Day 1414.818.1
Day 1516.720.2
Day 1620.422.3
Day 1723.124.5
Day 1825.028.7
Day 1926.929.8
Day 2029.933.2
Day 2132.2NA
Day 2236.236.4
Day 2342.040.1
Day 24NA45.6
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.7999
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data collected between Day 0 and 22 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 22
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 125.429.5
Day 2NA31.1
Day 327.132.8
Day 4NA36.1
Day 528.839.3
Day 630.542.6
Day 733.947.5
Day 835.649.2
Day 9NA52.5
Day 1140.755.7
Day 1244.159.0
Day 13NA62.3
Day 14NA63.9
Day 15NA67.2
Day 1647.5NA
Day 1749.268.9
Day 1854.272.1
Day 1955.973.8
Day 20NA77.5
Day 21NA79.4
Day 2258.184.5
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0059
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 58.7NA
Day 913.05.3
Day 1117.4NA
Day 12NA10.5
Day 13NA15.8
Day 14NA26.3
Day 1921.731.6
Day 2026.3NA
Day 2130.9NA
Day 2235.939.2
Day 23NA59.5
Day 24NA100.0
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.5520
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 24
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 119.332.7
Day 222.034.5
Day 3NA35.4
Day 424.8NA
Day 5NA38.1
Day 6NA40.7
Day 7NA42.5
Day 826.6NA
Day 930.3NA
Day 10NA45.2
Day 1131.249.7
Day 1233.051.5
Day 1335.855.1
Day 1536.756.0
Day 1639.457.8
Day 1743.258.7
Day 18NA61.4
Day 1944.162.3
Day 2048.265.1
Day 2150.6NA
Day 2256.1NA
Day 23NA69.0
Day 24NA75.2
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0175
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe: 4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. Data not collected shown as NA=Not Applicable.

Time frame:
Day 0 to Day 23
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 91.9NA
Day 12NA2.4
Day 133.74.8
Day 1411.19.5
Day 1513.014.3
Day 1616.7NA
Day 17NA16.7
Day 1820.423.8
Day 1922.3NA
Day 2024.329.1
Day 2126.5NA
Day 2229.036.2
Day 2343.2NA
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.7505
SecondarySeverity of Symptoms of Heartburn in Subgroup Stratified by Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.

Time frame:
Up to Week 4
Reported as:
Median · score on a scale
Severity of Symptoms of Heartburn in Subgroup Stratified by Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)
score on a scalePlaceboTAK-438 10 mg
Criteria 1, Grade N and Improved0.510 (0.00 to 1.31)0.430 (0.00 to 1.56)
Criteria 1, Grade N and Not Improved1.375 (0.59 to 2.82)1.240 (0.14 to 2.48)
Criteria 1, Grade M and Improved0.420 (0.00 to 1.44)0.280 (0.00 to 1.20)
Criteria 1, Grade M and Not Improved1.430 (0.25 to 2.54)1.520 (0.14 to 2.64)
Criteria 2, Grade N and Improved1.000 (0.00 to 2.00)0.640 (0.00 to 1.68)
Criteria 2, Grade N and Not Improved1.460 (0.60 to 2.82)1.695 (0.48 to 3.67)
Criteria 2, Grade M and Improved0.890 (0.00 to 2.14)0.710 (0.00 to 2.04)
Criteria 2, Grade M and Not Improved1.645 (0.44 to 2.54)1.790 (0.43 to 2.64)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.7845 · Median difference (final values): -0.0300 · 95% CI -0.2300 to 0.1600
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.4456 · Wilcoxon rank-sum test: -0.1100 · 95% CI -0.3300 to 0.1700
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0200 · Median difference (final values): -0.1500 · 95% CI -0.2900 to -0.0200
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.4673 · Median difference (final values): 0.0600 · 95% CI -0.1000 to 0.2200
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.0095 · Median difference (final values): -0.2900 · 95% CI -0.5300 to -0.0700
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1650 · Median difference (final values): 0.3100 · 95% CI -0.1600 to 0.7100
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.2475 · Median difference (final values): -0.0800 · 95% CI -0.2400 to 0.0700
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.2367 · Median difference (final values): 0.1300 · 95% CI -0.0900 to 0.3200
SecondaryPercentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher score indicates greater severity. The percentage was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].

Time frame:
Up to Week 4
Reported as:
Median · percentage of days
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History
percentage of daysPlaceboTAK-438 10 mg
Improved61.30 (0.0 to 100.0)71.40 (0.0 to 100.0)
Not Improved49.30 (0.0 to 100.0)80.80 (39.3 to 100.0)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1885 · Median difference (final values): 5.500 · 95% CI -2.700 to 14.300
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.2337 · Wilcoxon rank-sum test: 25.600 · 95% CI -19.200 to 75.000
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved) to Acid Suppressants in Participants Who Had a Medication History

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23. Data not collected were shown as NA=Not Applicable.

Time frame:
Up to Week 4
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved) to Acid Suppressants in Participants Who Had a Medication History
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 113.325.0
Day 215.726.2
Day 418.1NA
Day 520.5NA
Day 621.727.3
Day 7NA28.5
Day 822.929.6
Day 925.3NA
Day 10NA30.8
Day 11NA35.4
Day 1226.5NA
Day 13NA41.2
Day 1428.942.3
Day 1530.143.5
Day 1631.3NA
Day 1732.6NA
Day 1833.846.9
Day 1935.0NA
Day 2036.349.4
Day 21NA50.8
Day 2241.654.5
Day 2348.961.0
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0811
SecondaryCumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved) to Acid Suppressants in Participants Who Had a Medication History

Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 5, 9, 16, 19, and 20. Data not collected were shown as NA=Not Applicable.

Time frame:
Up to Week 4
Reported as:
Number · percentage of participants
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved) to Acid Suppressants in Participants Who Had a Medication History
percentage of participantsPlaceboTAK-438 10 mg
Day 00.00.0
Day 125.040.0
Day 5NA60.0
Day 9NA80.0
Day 1637.5NA
Day 19NA100.0
Day 2050.0NA
Statistical analysis
  • Placebo vs TAK-438 10 mg · Log Rank · p = 0.0288
SecondarySeverity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History

Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].

Time frame:
Up to Week 4
Reported as:
Median · score on a scale
Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History
score on a scalePlaceboTAK-438 10 mg
Improved1.150 (0.00 to 2.82)1.040 (0.00 to 3.67)
Not Improved1.280 (0.00 to 2.00)1.030 (0.18 to 1.68)
Statistical analysis
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.1488 · Median difference (final values): -0.1700 · 95% CI -0.4200 to 0.0400
  • Placebo vs TAK-438 10 mg · Wilcoxon Rank-Sum Test · p = 0.3778 · Wilcoxon rank-sum test: -0.4400 · 95% CI -1.5700 to 0.6900

Adverse events

Collected over Up to Week 4. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/245 (0%)1/245 (0.4%)12/245 (4.9%)
TAK-438 10 mg0/238 (0%)0/238 (0%)10/238 (4.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboTAK-438 10 mg
Colitis ulcerativeGastrointestinal disorders1/2450/238
Most frequent other events
Most frequent other events
EventPlaceboTAK-438 10 mg
Viral upper respiratory tract infectionInfections and infestations12/24510/238

Baseline characteristics

Randomized Set included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)PlaceboTAK-438 10 mgTotal
Mean51.8 ± 15.3852.8 ± 14.3752.3 ± 14.88
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-438 10 mgTotal
Female140161301
Male10578183
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PlaceboTAK-438 10 mgTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)PlaceboTAK-438 10 mgTotal
Japan245239484
Height
Height(cm)PlaceboTAK-438 10 mgTotal
Mean161.7 ± 8.62160.5 ± 9.29161.1 ± 8.97
Weight
Weight(kg)PlaceboTAK-438 10 mgTotal
Mean59.6 ± 12.0458.7 ± 11.1559.2 ± 11.61
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboTAK-438 10 mgTotal
Mean22.67 ± 3.43122.71 ± 3.37522.69 ± 3.400
Smoking Classification
Smoking Classification(Participants)PlaceboTAK-438 10 mgTotal
Never Smoked124128252
Current Smoker524496
Ex-smoker6967136

33 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Abiko, Chiba, Japan
  • Yachiyo, Chiba, Japan
  • Kasuya-gun, Fukuoka, Japan
  • Kasuya, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Yukuhashi, Fukuoka, Japan
  • Koriyama, Fukushima, Japan
  • Asahikawa, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Yokohama, Kanagawa, Japan
  • Suzaki, Kochi, Japan
  • Kitakatsuragi, Nara, Japan
  • Fujimi, Saitama, Japan
  • Hiki-gun, Saitama, Japan
  • Satte, Saitama, Japan
  • Otawara, Tochigi, Japan
  • Arakawa-ku, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
  • Toshima-ku, Tokyo, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Nagasaki, Japan
  • Oita, Japan
  • Osaka, Japan
  • Shizuoka, Japan
  • Yamagata, Japan
09

References and documents

Publications

  • Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, Iwakiri K, Ashida K. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study. Clin Transl Gastroenterol. 2019 Nov;10(11):e00101. doi: 10.14309/ctg.0000000000000101. PubMed 31770139 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Feb 2018, 15 months.

Results were first posted in Aug 2019, 1 year 5 months after primary completion.

Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 4, 2016
StartActual
Nov 15, 2016
Primary completionActual
Feb 25, 2018
CompletionActual
Feb 26, 2018
Results first posted
Aug 2, 2019
Last update
Aug 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02954848
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Nov 15, 2016
Primary completion
Feb 25, 2018
Completion
Feb 26, 2018
Results posted
Aug 2, 2019
Last update
Aug 2, 2019

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion